We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Long, Noncoding RNA Linked to Lung Cancer Metastasis

By LabMedica International staff writers
Posted on 20 Feb 2013
A recent paper described the functional significance of the long, noncoding RNA (lncRNA) MALAT1 in the process of lung cancer metastasis.

The vast majority of RNA molecules are transcribed by DNA segments that do not code for proteins. More...
These RNAs, which arbitrarily have been defined as containing more than 200 nucleotides, are called long, noncoding RNAs and are clearly differentiated from small, inhibitory RNAs such as short, inhibitory RNA (siRNA) and microRNA (miRNA).

MALAT1 (metastasis associated lung adenocarcinoma transcript 1) also known as NEAT2 (noncoding nuclear-enriched abundant transcript 2) is a large, infrequently spliced noncoding RNA. This molecular species is expressed in the nucleus and is highly conserved among mammals. It is associated with metastasis, and positively regulates cell motility via the transcriptional and/or post-transcriptional regulation of motility-related genes.

To study the role of MALAT1 in metastasis investigators at the German Cancer Research Center (Heidelberg) developed a MALAT1 knockout model in human lung tumor cells by genomically integrating RNA destabilizing elements using zinc finger nucleases that destroyed molecules of MALAT1 as soon as they were manufactured. In this manner, the investigators were able to silence MALAT1 expression by reducing the level of this molecular species in lung cancer cells by more than 1,000-fold.

The investigators reported in the December 14, 2012, online edition of the journal Cancer Research that the MALAT1-deficient cells were impaired in migration and formed fewer tumor nodules in a mouse xenograft.

Mice that had been injected with human lung cancer cells were treated with antisense oligonucleotides directed at MALAT1. This treatment prevented metastasis formation after tumor implantation. The animals' lungs showed fewer and smaller tumor nodules than those of control animals that had not been given the antisense nucleotides.

"The more MALAT1 tumor cells produce, the higher the odds for metastasis and a very unfavorable course of the disease," said senior author Dr. Sven Diederichs, a group leader in molecular RNA biology and cancer at the German Cancer Research Center. "Ten years after we discovered MALAT1 as a predictive marker in lung cancer, we now understand how this noncoding RNA influences metastasis. Moreover, this RNA has turned out to be a potential target for an innovative treatment with antisense RNAs."

Related Links:
German Cancer Research Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.